Bli medlem
Bli medlem

Du är här

2015-03-25

Nexstim Oyj: Nexstim Plc ("Nexstim" or the "Company") Board Change

Helsinki, 25thMarch 2015 at 8:00 am

Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company aiming to
improve rehabilitation for stroke patients through the use of non-invasive
brain stimulation, announces that Tim Irish has been required to step down as
Chairman due to a conflict with the current process relating to his
prospective role as a Non-Executive Director of the United Kingdom's National
Institute of Health and Care Excellence (NICE). Until the next General
Meeting, Vice Chairman, Olli Riikkala, will act as chair of the Board of
Directors.

Commenting on the announcement, Tim Irish, said:
"Nexstim has extremely exciting brain stimulation technology that could have
major importance, particularly in the treatment of stroke. The Company
recently completed its successful IPO and, with its strong management team, I
have no doubt that it is en route to commercial success with an important
Phase III trial running. I have greatly enjoyed working with the team in
Finland and feel I leave the Company in a strong position for both the
patients and shareholders."

Nexstim's Vice Chairman, Olli Riikkala, added:
"Tim has made a valuable contribution to Nexstim in guiding the company to
this stage in its development. We thank him for his input over the past three
years and wish him well for the future."

NEXSTIM PLC
Janne Huhtala, Chief Executive Officer

For further information please visit
www.nexstim.comor contact:

Nexstim

+358 (0)40 8615046
Janne Huhtala, Chief Executive Officer
janne.huhtala@nexstim.com

UB Capital Oy
(Certified Adviser)
+358 (0)9 2538 0225

Consilium Strategic Communications

+44 (0)20 3709 5700
Mary-Jane Elliott / Ivar Milligan
nexstim@consilium-comms

About Nexstim Plc

Nexstim, formed in 2000 and based in Finland, is a medical technology company
aiming to improve rehabilitation for stroke patients. Nexstim has pioneered
its technology in brain diagnostics with the Navigated Brain Stimulation
(NBS) system as the first and only FDA-cleared and CE-marked navigated
Transcranial Magnetic Stimulation (nTMS) device for pre-surgical mapping of
the motor and speech cortices. Based on the same technology platform, the
company has developed a device for stroke therapy called Navigated Brain
Therapy (NBT®). In H1 2014, Nexstim initiated a two-year pivotal Phase III
study at 12 sites in the US aiming to demonstrate the effectiveness of NBT®
and gain FDA clearance for commercialisation in post-acute stroke therapy in
the US. Nexstim's shares are listed on Nasdaq First North Finland and Nasdaq
First North Sweden. For more information please visit www.nexstim.com.

Nexstim regulatory release ENG
http://hugin.info/138152/R/1905964/678412.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Nexstim Oyj via Globenewswire

HUG#1905964

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.